ALS Invest 1 B.V.
Known title: 10% OwnerCIK: 0001920501
Associated companies
Transaction History
| AMLX | ▼ Sell | Open Market | 18,312 | $358K | 7/6/2022 | View on chart |
| AMLX | ▼ Sell | Open Market | 10,395 | $214K | 7/6/2022 | View on chart |
| AMLX | ▼ Sell | Open Market | 29,595 | $631K | 7/6/2022 | View on chart |
| AMLX | ▼ Sell | Open Market | 2,307 | $52K | 7/6/2022 | View on chart |
| AMLX | ▼ Sell | Other | 1,129,386 | — | 1/11/2022 | View on chart |
| AMLX | ▼ Sell | Other | 4,826,503 | — | 1/11/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Amylyx to Present Phase 3 Avexitide Data at ObesityWeek 2026
Amylyx Pharmaceuticals is scheduled to present topline data from its Phase 3 LUCIDITY trial for avexitide at the ObesityWeek 2026 annual meeting. The data will focus on the drug's efficacy and safety in treating post-bariatric hypoglycemia. This upcoming presentation is a key catalyst for the company, as it provides new clinical evidence for a major therapeutic area.
Amylyx to Present Phase 3 Avexitide Data at ObesityWeek 2026. Amylyx Pharmaceuticals is scheduled to present topline data from its Phase 3 LUCIDITY trial for avexitide at the ObesityWeek 2026 annual meeting. The data will focus on the drug's efficacy and safety in treating post-bariatric hypoglycemia. This upcoming presentation is a key catalyst for the company, as it provides new clinical evidence for a major therapeutic area.